Latest news

6 years 11 months ago
Addaction is embracing World Hepatitis Day in a big way this year. Packs with promotional materials and information are being sent out to all participating services this week.
6 years 12 months ago
The Hepatitis C Trust has won a Communique Award for Excellence in Media Relations for its work with Paradigm Communications, in launching the report from the All-Party Parliamentary Hepatology Group's expert Inquiry into the burden of liver disease.
7 years 9 hours ago
All participants in the TURQUOISE-III trial, which enrolled HCV genotype 1b patients with compensated liver cirrhosis, achieved sustained virological response using AbbVie's Viekira Pak or "3D" regimen without ribavirin, according to a company announcement this week. The advent of interferon-free direct-acting antiviral therapy has revolutionized hepatitis C treatment. But challenges remain for the most difficult-to-treat patients, including those with advanced liver disease.
7 years 2 weeks ago
Health Secretary Jeremy Hunt must intervene to overturn attempts by NHS England to severely limit the number of people with hepatitis C receiving life-saving treatments, 14 charities and top liver doctors have written to him to say.
7 years 3 weeks ago
Today NHS England published a commissioning policy that will allow people with hepatitis C-related cirrhosis access to new treatments. NHS England has announced (10 June 2015) that it will be investing an estimated further £190 million in new cures for hepatitis C, on top of the approximately £40 million which began last year as part if its early access scheme to treat people with decompensated cirrhosis.
7 years 3 weeks ago
The estimated 37,000 people in Scotland with hepatitis C received the good news yesterday that the Scottish Medicines Consortium (SMC) has now approved Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir) for use within NHS Scotland.  Viekirax has been approved for use in combination with Exviera, with or without ribavirin, for the treatment of genotype 1 chronic hepatitis C in adults, while Viekirax has been approved for use in combination with ribavirin for the treatment of genotype 4 patients.
7 years 3 months ago
Picture of the Penrose inquiry report courtesy of the BBC. The Hepatitis C Trust has welcomed the long-awaited publication of the Penrose Inquiry’s report into hepatitis C/HIV acquired infection from NHS treatment in Scotland, and has urged that its key recommendation, that all people who received a blood transfusion prior to September 1991 be tested for hepatitis C, be implemented across the UK as a matter of urgency.
7 years 4 months ago
In draft guidance published today healthcare guidance body NICE has recommended ledipasvir-sofosbuvir (Harvoni) as a treatment option for some adults with genotype 1 or 4 chronic hepatitis C. The Committee also considered ledipasvir-sofosbuvir in combination with ribavirin  for people with genotype 3 chronic hepatitis C. Based on the evidence presented the Committee concluded that this could not be considered a cost-effective use of NHS resources.
7 years 4 months ago
Click here to read the full published report  London accounts for nearly a third of all newly diagnosed cases of hepatitis C reported in England, with 3,079 new laboratory reports of confirmed diagnoses reported in 2013, a rise of 12% since 2012. London also has the second highest rate of diagnosis per head of population, after Greater Manchester.
7 years 5 months ago
MSPs from the Scottish Parliament’s three largest parties used the opportunity afforded by a debate on hepatitis C in Scotland to unite in calling for the Scottish Government to commit to the elimination of hepatitis C, and to express their support for the estimated 37,000 people affected by the virus in Scotland.